US 11,786,482 B2
Compositions and methods using a cannabinoid to enhance bioavailability of a statin
James Smeeding, Dallas, TX (US); and Mathew Sherwood, Silverthorne, CO (US)
Assigned to Indication BioScience LLC, Dover, DE (US)
Filed by Indication BioScience LLC, Silverthorne, CO (US)
Filed on Jan. 3, 2022, as Appl. No. 17/567,653.
Application 17/567,653 is a continuation of application No. 17/075,586, filed on Oct. 20, 2020, granted, now 11,234,944, issued on Feb. 1, 2022.
Application 17/075,586 is a continuation of application No. 16/338,663, granted, now 10,835,501, issued on Nov. 17, 2020, previously published as PCT/US2017/054685, filed on Oct. 1, 2017.
Claims priority of provisional application 62/403,067, filed on Oct. 1, 2016.
Prior Publication US 2023/0055662 A1, Feb. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 31/22 (2006.01); A61K 31/352 (2006.01); A61K 31/366 (2006.01); A61K 31/47 (2006.01); A61K 31/505 (2006.01); A61K 36/185 (2006.01); A61K 9/00 (2006.01); A61P 9/10 (2006.01); A61P 21/00 (2006.01); A61K 31/405 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 9/006 (2013.01); A61K 31/22 (2013.01); A61K 31/352 (2013.01); A61K 31/366 (2013.01); A61K 31/405 (2013.01); A61K 31/47 (2013.01); A61K 31/505 (2013.01); A61K 36/185 (2013.01); A61P 9/10 (2018.01); A61P 21/00 (2018.01)] 20 Claims
 
1. A pharmaceutical composition for once daily dosing, useful in enhancing the bioavailability upon oral administration to a human patient of a statin, comprising:
(a) a reduced daily dosage amount of the statin; and
(b) a phytocannabinoid;
wherein the pharmaceutical composition is formulated for oral administration, and wherein the reduced daily dosage amount of the statin is less than the standard daily dosage amount for the statin when taken alone.